Compare ON & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ON | RVMD |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5B | 19.1B |
| IPO Year | 2000 | N/A |
| Metric | ON | RVMD |
|---|---|---|
| Price | $61.91 | $97.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 18 |
| Target Price | $64.46 | ★ $117.33 |
| AVG Volume (30 Days) | ★ 6.2M | 1.5M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $5,878,300,000.00 | N/A |
| Revenue This Year | $7.85 | N/A |
| Revenue Next Year | $8.78 | $408.69 |
| P/E Ratio | $192.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.04 | $29.17 |
| 52 Week High | $73.76 | $124.49 |
| Indicator | ON | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.65 | 49.30 |
| Support Level | $52.58 | $93.86 |
| Resistance Level | $63.63 | $107.45 |
| Average True Range (ATR) | 2.43 | 3.23 |
| MACD | 0.08 | -0.27 |
| Stochastic Oscillator | 75.34 | 58.45 |
Onsemi is a supplier of power semiconductors and sensors focused on the automotive and industrial markets. Onsemi is the second-largest power chipmaker in the world and the largest supplier of image sensors to the automotive market. While the firm used to be highly vertically integrated, it now pursues a hybrid manufacturing strategy for flexible capacity. Onsemi is pivoting to focus on emerging applications like electric vehicles, autonomous vehicles, industrial automation, and renewable energy.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.